BOSTON, April 1, 2019 /PRNewswire/ -- IFM Therapeutics (IFM), a privately held biopharmaceutical company focused on developing therapies that modulate novel targets in the innate immune system, announced today that it has reached a definitive agreement with Novartis, under which Novartis...
from PR Newswire: https://ift.tt/2HQIMUg
No comments:
Post a Comment